Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus
NCT04931563Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing placebo with anifrolumab (2 arms). Primary endpoint: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo at 52 weeks. Started Sep 2021; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04931563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931563.